Uppsala Reports is the UMC's regular news bulletin for everyone concerned with the issues of pharmacovigilance. If you wish to go on the mailing list please send your details to firstname.lastname@example.org.
Uppsala Reports 73 - September 2016 - is out now!
As ever Uppsala Reports has lots of reports from the UMC and around the world of pharmacovigilance. At the Uppsala Forum the road to faster access to novel medicines was discussed - we have several features on key talks. The diagnosis and treatment of women’s health concerns, and the risk communication accompanying them, was recently promoted by an innovative conference poster presentation. Faster reporting of adverse effects can be boosted by using mobile technologies to collect and present important medicines safety information, such as the WEB-RADR project. In an opinion piece the question is posed as how the sub-Saharan research community needs true international partners to help build its scientific capacity. We also have a look at the 2016 new full and associate members of the WHO Programme for International Drug Monitoring. All this as well as Japan’s model for post-marketing medicines safety, the perpetual pursuit of evidence-based medicine and its importance for pharmacovigilance and the latest news in harmonizing pharmacovigilance in Central America.
For Uppsala Reports 72 we made many changes: a new design language and brand identity reflect the fact that the Uppsala Reports is a global entity and covers the whole world of pharmacovigilance. You’ll find new ideas for columns, new writers, new page designs, and a new spirit of inquiry that is both revolutionary and genuine. The latest edition of Uppsala Reports contains a wide range of news from around the world of pharmacovigilance, including regional initiatives from all corners of the globe.
As our main feature we interview Dr Andrea Marzi and put Ebola under the microscope, looking at developing an Ebola vaccine in the midst of an outbreak. We also examine the current trends in adverse drug reaction reporting and explore the recent UMC research paper “Quantitative benefit–risk assessment of methylprednisolone in multiple sclerosis relapses”.
Uppsala Reports is your magazine – just like it’s always been – and we would love to hear what you think about the new look; please e-mail us with comments and suggestions. (Please click on this link to get the 4.6Mb pdf of UR72.)
For all the previous issues of Uppsala Reports since 1996, click on Uppsala Reports Archive.
Uppsala Reports page last updated 30 September 2016
Uppsala Monitoring Centre · Tel: +46 18 65 60 60 · Fax: +46 18 65 60 88